Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Stahel, R.; Bogaerts, J.; Ciardiello, F.; de Ruysscher, D.; Dubsky, P.; Ducreux, M.; Finn, S.; Laurent-Puig, P.; Peters, S.; Piccart, M.; Smit, E.; Sotiriou, C.; Tejpar, S.; Van Cutsem, E.; Tabernero, J.
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 2(2015)
• Page Start: 129
• Page End: 135
• Publication Date: 2015-02
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2014.12.004
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab010"> <title id="st085">Highlights</title> <sec> <p id="sp0030"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0130">Treatment advances in oncology are limited and new approaches are needed.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0135">Tumour heterogeneity is a key issue underlying this lack of progress.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0140">Molecular characterisation of cancer subtypes could transform future treatment.</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0145">Clinical trial recruitment for rare cancer subtypes is challenging.</p> </list-item> <list-item id="o0025"> <label></label> <p id="p0150">Potential collaborative approaches designed to accelerate progress are discussed.</p> </list-item> </list> </p> </sec> </abstract>